Trial Profile
A prospective registry trial of dasabuvir, ombitasvir/paritaprevir/ritonavir (DSV+OBV/PTV/r) for HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease:The Madrid co-infection registry (MADRID-CoRe)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C; Liver disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms MADRID-CoRe
- 30 Dec 2016 New trial record